Effect: Voriconazole may increase the plasma concentrations of buprenorphine.
Clinical management: Caution should be exercised upon coadministration of these drugs. Monitor for increased buprenorphine toxicity.
Probable mechanism: Inhibition of the cytochrome P450 (CYP) 3A4-mediated biotransformation by voriconazole.
Summary: Although coadministration of voriconazole and buprenorphine has not been studied, in vitro data show that buprenorphine is a substrate of CYP3A4. Coadministration with the CYP3A4 inhibitor voriconazole may increase plasma concentrations of buprenorphine.
- SPC Buprenorphine
QT effectVoriconazole: Conditional QT risk
Substantial evidence reports that this drug causes QT prolongation and has a risk of TdP, but only under certain known conditions (e.g. excessive dose, drug interaction, etc.).
Substantial evidence reports that this drug prolongs the QT interval and has a risk of causing TdP (when used as directed in labeling).